Demonstrates modularity of Intellia’s in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy Single-course administration of genome editing system provides ...
Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results